The approval is the first new treatment advance in more than 30 years for chronic kidney disease for adults with type 1 diabetes.
News|Articles|February 15, 2019
Generic Tolterodine Tartrate ER Capsules for Overactive Bladder
Author(s)Drew Boxler
Advertisement
Generic Detrol LA® (tolterodine tartrate extended release capsules, Chamber® Pharmaceuticals, Inc.)
Indications: overactive bladder with symptoms of urinary incontinence, urgency, and frequency.
Dosage
- 4mg capsules taken orally 1x day w/water
- 2 mg capsules taken orally 1xday with water if...
- mild to moderate hepatic impairment (Child-Pugh class A or B)
- severe renal impairment [Creatinine Clearance (CCr) 10–30 mL/min]
- drugs that are potent CYP3A4 inhibitors
Contraindications
- Urinary retention
- Gastric retention
- Uncontrolled narrow-angle glaucoma
- Known hypersensitivity to the drug or its ingredients, or fesoterodine fumarate ER tablets
Advertisement
Related to this article
The approval extends the medication to a younger pediatric population, marking the first FDA-approved treatment for children with this immunodeficiency.
Results show consistent improvements in wakefulness, cataplexy, and quality of life with oveporexton for patients with narcolepsy.
Researchers assess the differences in out-of-pocket spending on brand name compared with generic medication.
Practical takeaways to improve real‑world clinic outcomes for PAINWeek 2026.
Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.
The trial found that up to 25 days of nirmatrelvir-ritonavir did not improve cognitive, autonomic, or exercise-related symptoms compared with placebo.
Digital innovation and proactive patient care are converging to transform clinical practice while preserving essential safeguards.
Advertisement
Advertisement
Trending on Drug Topics
1
Johnson & Johnson Next Major Drugmaker to Require 340B Claims Data
2
Expert Discusses Flu and COVID-19 Vaccine Guidance
3
Nirmatrelvir-Ritonavir Shows No Benefit for Long COVID
4
Generic Drug Costs Burdening Patients as Much as Brand Name Options
5